Skip to the page

Data / Drug companies / Pfizer Laboratories Div Pfizer Inc

Pfizer Laboratories Div Pfizer Inc: 172 products in the FDA NDC directory, labeler code 0069

Updated November 6, 2026. Source: US Food and Drug Administration, National Drug Code Directory (openFDA).

Pfizer Laboratories Div Pfizer Inc (labeler code 0069) lists 172 products in the FDA National Drug Code Directory, covering 49 finished drugs by generic name. By type: 143 prescription drugs, 21 plasma derivatives. Its main marketing category is new drug applications (NDA). The newest product started marketing on August 27, 2026.

The request: Watch Pfizer Laboratories Div Pfizer Inc (FDA labeler code 0069): each new product listing and each discontinued product. $10 of work on sign-up, no card.

SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.

Labeler code
0069
Products in commercial distribution
172
Packages
192
Finished drugs by generic name
49
Prescription products
143
Over the counter products
0
Flagged as original packager
113 of 113 products that carry the flag
Started marketing in the last 12 months
5
Products with a marketing end date set
19
Earliest marketing start
September 6, 1989
openFDA record search
api.fda.gov

Products by marketing category

Share of the company's products in commercial distribution.

Marketing categoryProductsShare
New drug applications (NDA)11265.1%
Biologics (BLA)5632.6%
Generic drugs (ANDA)31.7%
Unapproved drugs for a shortage10.6%

Products by type

TypeProductsShare
Prescription drugs14383.1%
Plasma derivatives2112.2%
Vaccines84.7%

Drugs it lists

Finished drugs by generic name, with how many companies list each.

DrugProductsCompanies listing it
Doxorubicin hydrochloride1020
Dalteparin sodium91
Talazoparib92
Immune globulin92
Azithromycin dihydrate820
Amlodipine and atorvastatin89
Epoetin alfa-epbx72
Palbociclib62
Immune globulin intravenous (human)63
Immunoglobulin g62
Tofacitinib523
Bosutinib55
Nirmatrelvir and ritonavir51
Crizotinib51
Filgrastim-aafi41
Sunitinib malate49
Sildenafil citrate424
Covid-19 vaccine, mrna42
Abrocitinib32
Amlodipine besylate349
Propofol315
Varenicline tartrate323
Dacomitinib31
Fosphenytoin sodium38
Dofetilide312
Marstacimab-hncq31
Fesoterodine fumarate212
Glasdegib21
Nifedipine238
Axitinib22
Rituximab-pvvr21
Bevacizumab-bvzr21
Somatrogon-ghla21
Lorlatinib22
Trastuzumab-qyyp21
Tick-borne encephalitis vaccine21
Elranatamab-bcmm22
Heparin sodium123
Infliximab-dyyb12
Tafamidis11
Tafamidis meglumine11
Ritlecitinib12
Calcium folinate12
Meningococcal groups a, b, c, w, and y vaccine11
Zavegepant12
Taliglucerase alfa11
Pegfilgrastim-apgf11
Etrasimod11
Respiratory syncytial virus vaccine12

Dosage forms

Dosage formProductsShare
Tablet, film coated3822.1%
Injection, solution3620.9%
Solution2212.8%
Capsule1810.5%
Injection127%
Capsule, liquid filled84.7%
Kit84.7%
Tablet, film coated, extended release63.5%
Injection, powder, lyophilized, for solution63.5%
Tablet42.3%
Injection, suspension42.3%
Powder, for suspension31.7%

Pharmacologic classes

FDA established pharmacologic classes of its products.

Newest products

By marketing start date.

ProductProduct NDCDosage formMarketing categoryMarketing start
Comirnaty0069-2631Injection, suspensionBiologics (BLA)August 27, 2026
Comirnaty0069-2609Injection, suspensionBiologics (BLA)August 27, 2026
Hympavzi0069-0775Injection, solutionBiologics (BLA)June 22, 2026
Paxlovid0069-5450KitNew drug applications (NDA)January 5, 2026
Lederle leucovorin0069-5886TabletUnapproved drugs for a shortageDecember 18, 2025
Hympavzi0069-1510Injection, solutionBiologics (BLA)October 15, 2025
Comirnaty0069-2528Injection, suspensionBiologics (BLA)August 27, 2025
Comirnaty0069-2501Injection, suspensionBiologics (BLA)August 27, 2025
Paxlovid0069-5434KitNew drug applications (NDA)July 9, 2025
Paxlovid0069-5045KitNew drug applications (NDA)July 9, 2025
Doxorubicin Hydrochloride0069-5629Injection, solutionNew drug applications (NDA)March 31, 2025
Doxorubicin Hydrochloride0069-4031Injection, solutionNew drug applications (NDA)March 31, 2025
Doxorubicin Hydrochloride0069-4205Injection, solutionNew drug applications (NDA)November 11, 2024
Doxorubicin Hydrochloride0069-3358Injection, solutionNew drug applications (NDA)November 11, 2024
Doxorubicin Hydrochloride0069-0343Injection, solutionNew drug applications (NDA)November 11, 2024
Hympavzi0069-2151Injection, solutionBiologics (BLA)November 5, 2024
Doxorubicin Hydrochloride0069-1442Injection, solutionNew drug applications (NDA)October 14, 2024
Doxorubicin Hydrochloride0069-0255Injection, solutionNew drug applications (NDA)October 14, 2024
Doxorubicin Hydrochloride0069-0358Injection, solutionNew drug applications (NDA)August 19, 2024
Doxorubicin Hydrochloride0069-0277Injection, solutionNew drug applications (NDA)August 19, 2024
Abrysvo0069-2465Injection, powder, lyophilized, for solutionBiologics (BLA)July 30, 2024
Doxorubicin Hydrochloride0069-1542Injection, solutionNew drug applications (NDA)July 22, 2024
Talzenna0069-0757Capsule, liquid filledNew drug applications (NDA)April 17, 2024
Talzenna0069-0655Capsule, liquid filledNew drug applications (NDA)April 17, 2024
Talzenna0069-0546Capsule, liquid filledNew drug applications (NDA)April 17, 2024

CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.